General Information of Drug Combination (ID: DC3M762)

Drug Combination Name
BIO-300 Vincristine
Indication
Disease Entry Status REF
Minimally invasive lung adenocarcinoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Vincristine   DMINOX3
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: NCI-H322M
Zero Interaction Potency (ZIP) Score: 3.94
Bliss Independence Score: 8.81
Loewe Additivity Score: 9.36
LHighest Single Agent (HSA) Score: 9.66

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Vincristine
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [4]
Adult kidney Wilms tumor N.A. Approved [5]
Beckwith-Wiedemann syndrome N.A. Approved [5]
Burkitt lymphoma N.A. Approved [5]
Central nervous system neoplasm N.A. Approved [5]
Childhood acute lymphoblastic leukemia N.A. Approved [5]
Childhood kidney Wilms tumor N.A. Approved [5]
Hamartoma N.A. Approved [5]
Kidney neoplasm N.A. Approved [5]
Leukemia N.A. Approved [5]
MALT lymphoma N.A. Approved [5]
Nodal marginal zone lymphoma 2A85.0 Approved [5]
Plasma cell myeloma 2A83.1 Approved [5]
Primitive neuroectodermal tumor N.A. Approved [5]
Splenic marginal zone lymphoma N.A. Approved [5]
Testicular lymphoma N.A. Approved [5]
Wilms tumor N.A. Approved [5]
Classic Hodgkin lymphoma N.A. Investigative [5]
Follicular lymphoma 2A80 Investigative [5]
Neuroblastoma 2D11.2 Investigative [5]
Vincristine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
Vincristine Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [7]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
------------------------------------------------------------------------------------
Vincristine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [11]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [12]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCFXLB3 MOLT-4 Investigative [13]
Anaplastic large cell lymphoma DCREU0P SR Investigative [13]
Astrocytoma DC52PE0 U251 Investigative [13]
Childhood T acute lymphoblastic leukemia DC0EHOB CCRF-CEM Investigative [13]
Chronic myelogenous leukemia DCKXUPC K-562 Investigative [13]
Clear cell renal cell carcinoma DCSY7LN A498 Investigative [13]
Clear cell renal cell carcinoma DCXYX9X TK-10 Investigative [13]
Clear cell renal cell carcinoma DC5M3DL CAKI-1 Investigative [13]
Glioma DC4U7HV SF-268 Investigative [13]
Glioma DCYOJTX SF-539 Investigative [13]
Glioma DC3DUFW SF-295 Investigative [13]
Renal cell carcinoma DC6LBV9 SN12C Investigative [13]
Carcinoma DCHXL81 RXF 393 Investigative [14]
Carcinoma DC2X6UN MCF7 Investigative [14]
Colon adenocarcinoma DCPD3VR COLO 205 Investigative [14]
Adenocarcinoma DCAEIHX DU-145 Investigative [1]
Adenocarcinoma DCT0YWC OVCAR3 Investigative [1]
Adenocarcinoma DCKPBVF NCIH23 Investigative [1]
Adenocarcinoma DC6IXPW A549 Investigative [1]
Adenocarcinoma DCA8125 HCT-15 Investigative [1]
Adenocarcinoma DCNF0QM SW-620 Investigative [1]
Adenocarcinoma DC6DSUS HCT116 Investigative [1]
Amelanotic melanoma DCSUW6Q M14 Investigative [1]
High grade ovarian serous adenocarcinoma DCVFN7D OVCAR-5 Investigative [1]
Large cell lung carcinoma DCWMU5H NCI-H460 Investigative [1]
Lung adenocarcinoma DC0DFK4 HOP-62 Investigative [1]
Malignant melanoma DCP5CBG UACC62 Investigative [1]
Mixed endometrioid and clear cell carcinoma DCQCZ2Q IGROV1 Investigative [1]
Non-small cell lung carcinoma DC7MK4Y HOP-92 Investigative [1]
Ovarian serous cystadenocarcinoma DCX2L4H SK-OV-3 Investigative [1]
Pleural epithelioid mesothelioma DCGKVQS NCI-H226 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 31 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
5 Vincristine FDA Label
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
10 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
11 Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
12 Drug Interactions Flockhart Table
13 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
14 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.